INDWELLING BODY LUMEN EXPANDER
20190117423 ยท 2019-04-25
Assignee
Inventors
- Tiffany E. CHAO (Palo Alto, CA, US)
- Nicholas R. DAMIANO (San Francisco, CA, US)
- Shreya Mehta (San Francisco, CA, US)
- John P. WOOCK (Irvine, CA, US)
Cpc classification
A61F2/86
HUMAN NECESSITIES
A61F2/89
HUMAN NECESSITIES
A61F2/848
HUMAN NECESSITIES
International classification
A61F2/89
HUMAN NECESSITIES
A61F2/04
HUMAN NECESSITIES
A61F2/86
HUMAN NECESSITIES
Abstract
Indwelling body lumen expanders which allow for the maintenance and patency of a body lumen, such as the prostatic urethra to relieve urethral obstruction, are described. Because the one or more expanders are configured to be relatively larger in diameter than the diameter of the body lumen, the expanders may become invaginated into the lumen wall thus enabling the prostheses to avoid fluid exposure which in turn prevent the prostheses from becoming encrusted or calcified.
Claims
1. A method for maintaining patency of a prostatic urethra lumen, comprising: advancing at least one expander structure into the prostatic urethra lumen which is to be maintained in an open configuration, wherein the expander structure is a unitary structure having ring-like structures formed by looping the expander structure, the ring-like structures being non-coplanar and coupled by tangential portions of the expander structure; and deploying the at least one expander structure against a tissue lining of the prostatic urethra lumen such that the ring-like structures of the expander structure define a deployment diameter sized to be 8 mm or greater such that the deployment diameter is relatively larger than an expanded diameter of the prostatic urethra lumen.
2. The method of claim 1, wherein deploying the at least one expander structure comprises altering the deployment diameter of the expander structure.
3. The method of claim 1, wherein the at least one expander structure has a height of between 0.2 mm to 1.5 mm.
4. The method of claim 1, wherein the at least one expander structure has a width of between 0.2 mm to 1.5 mm.
5. The method of claim 4, wherein deploying the at least one expander structure comprises deploying at least two or more ring-like structures spaced apart from one another.
6. The method of claim 1, wherein the at least one expander structure comprises one or more connecting elements coupling the two or more ring-like structures to each other.
7. The method of claim 1, further comprising deploying one or more additional expander structures against the tissue lining, wherein each of the expander structures arc spaced 3 mm to 20 mm apart from one another to facilitate tissue invagination.
8. The method of claim 1, wherein deploying comprises reconfiguring the at least one expander structure from a low profile configuration within the prostatic urethra lumen.
9. The method of claim 8, wherein deploying further comprises deploying the at least one expander structure against one or more lobes of a prostate.
10. A method for maintaining patency of a body lumen, comprising: advancing at least one expander structure into the body lumen which is to be maintained in an open configuration; and deploying the at least one expander structure from a low-profile configuration into a deployed configuration against a tissue lining of the body lumen such that the expander structure forms one or more ring-like structures coupled by tangential portions of the expander structure, where the ring-like structures arc formed by looping the expander structure to define a deployment diameter that is relatively larger than an expanded diameter of the body lumen.
11. The method of claim 10, wherein the deployment diameter is sized to be 8 mm or greater.
12. The method of claim 10, wherein the body lumen comprises a prostatic urethra lumen.
13. A method of deploying an expander, comprising: inserting the expander into a prostatic urethra, wherein the expander comprises an elongate wire that is expandable into a configuration having a plurality of ring-like structures in which the distal and proximal ring-like structures are partial rings and in which the ring-like structures are longitudinally spaced from each other by an elongate connector element extending from each ring-like structure to its adjacent ring-like structure; locating the expander in the prostatic urethra such that, upon expansion, the ring-like structures are capable of engaging a wall of the prostatic urethra; and expanding the expander into engagement with the wall of the prostatic urethra.
14. The method of claim 13, wherein the expander is self-expanding and is delivered in its collapsed state through a lumen of a deployment member.
15. The method of claim 14, wherein the deployment member is a cystoscope.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0033]
[0034]
[0035]
[0036]
[0037]
[0038]
[0039]
[0040]
[0041]
[0042]
[0043]
[0044]
[0045]
[0046]
[0047]
[0048]
[0049]
[0050]
[0051]
[0052]
[0053]
DETAILED DESCRIPTION OF THE INVENTION
[0054] The deployment of one or more expandable structures or scaffolds within the prostatic urethra PU may be used to maintain patency of the prostatic urethra PU against the enlarged prostate PR (shown superior to the sphincter SP) in order to enable a patient to urinate and thereby provide relief from urinary tract retention arising from conditions such as BPH. Such urethral expanding structures 10 may be deployed within the prostatic urethra PU and left as an indwelling prosthesis, as shown in the side view of
[0055]
[0056] The description of certain variations of the expanders are not intended to limit the scope of the present invention but other examples, features, aspects, embodiments, and advantages of the invention will become apparent to those skilled in the art from the description herein. Moreover, the expanders and their uses are capable of different and obvious aspects, all without departing from the scope of the invention. Accordingly, the drawings and descriptions should be regarded as illustrative in nature and not restrictive.
[0057] The various expander structures described are designed to expand the cross-sectional area of the prostatic urethra PU to allow urine drainage from the bladder BL. These expanders may be deployed to span the prostatic urethra PU and may be optionally anchored at their respective locations to prevent migration of the structure after deployment in the patient body. The deployed diameter of the expander structures may be configured to expand to a deployment diameter which is generally larger than that of the urethra, e.g., the deployed diameter may have a diameter which is, e.g., 0% to 60% or more preferably 10% to 40%, relatively larger than the typical diameter of a prostatic urethra PU. While the anatomy of individual patients will vary, the deployment diameter of the expander structure may range anywhere from, e.g., 8 mm to 16 mm. Alternatively, the diameter of a patient's prostatic urethra PU may be taken prior to delivery of the expanders and one or more of the expander structures having a diameter which is correspondingly larger in size than the patient's body lumen may be selected for deployment.
[0058] The one or more expander structures may also optionally incorporate a tissue anchoring mechanism which allows for the securement of the deployed expander directly into the surrounding luminal tissue walls to prevent migration of the structures. Moreover, the expander structures may be designed to have a height (the length of the expander along the luminal tissue wall) and width (wall thickness) which are sufficiently thin enough to allow for the luminal tissue to invaginate the expanders at least partially or completely into the urethral wall. The thinness of the expanders may facilitate the enfolding of the urethral tissue wall at least partially or completely around the expanders so that the structures remain out of the urine stream and are thereby protected from calcification or encrustation by the passing urine stream. For example, an expander may have a height ranging anywhere from, e.g., 0.2 mm to 1.5 mm, and a width ranging anywhere from, e.g., 0.2 mm to 1.5 mm, so long as the dimensions of the expander facilitate the eventual partial or complete invagination of the expander within the urethral tissue wall. Once one or more expanders have been deployed, partial or complete tissue epithelialization may take anywhere from, e.g., 2 to 8 weeks, given the size of the expanders and the nature of tissue along the urethral wall. The illustration shown in
[0059] Furthermore, the expanders may also optionally incorporate any number of surface textures or features such as openings along the surface of the expanders which may facilitate the invagination of the tissue wall. For instance, the surface of the expander may be electropolished to decrease friction of the expander during deployment from a delivery instrument. Alternatively, the surface of the expander could also be roughened or otherwise altered to increase friction and anchoring ability in the urethra. In yet another alternative, portions of the expander may be roughened, e.g., the outer surfaces which contact the tissue walls, while the remainder of the surfaces may remain smooth to facilitate delivery and deployment. Roughening the device in this manner could also serve to promote anchoring in the urethra or epithelialization into the urethral wall.
[0060] Moreover, the expanders may also optionally incorporate any number of eluting biologic agents, e.g., alpha-blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, etc. which may prohibit additional prostate growth. Alternatively, the expanders may also optionally incorporate any number of eluting biologic agents which block cell proliferation, e.g., paclitaxel, sirolimus, zirolimus, etc.
[0061] In other variations, the expander may be coated with or integrate a layer of material which is hydrophobic or superhydrophobic to further discourage fluid exposure of the expander structure to the urine.
[0062] Additionally, the expander may also optionally incorporate various mechanisms for emitting any number of forms of energy or the expanders may be used along with various forms of energy which may be administered separately from the expander. For instance, an expander may administer thermal, electrical, microwave, mechanical, etc. energy to the tissue prior to, during, or after deployment of the expander. The source of the energy may be controlled or delivered externally from the patient body, e.g., via ultrasound or magnetic induction.
[0063] Additionally, the expanders may be comprised of any number of biocompatible materials, e.g., metals such as Nitinol or stainless steel, plastics, polymers such as silicone, PET, PTFE, etc., etc., which may be utilized in any number of combinations either within a single expander or between several expanders utilized together. While the expander structure may remain within the tissue walls, portions of the expander or the entire expander structure may be optionally configured to biodegrade or bioabsorb over a specified period of time.
[0064] In the event that the expander is comprised of a shape memory alloy such as Nitinol, the expander may be configured to have a predetermined diameter and shape. Prior to and during deployment of the expander within the body lumen, the expander may have a collapsed low-profile configuration suitable for uninhibited delivery into the body lumen. Once the expander has been desirably positioned, the expander may be allowed to self-expand into its deployment configuration as it heats to body temperature, e.g., above 30 C. Alternatively, the expander may be actuated to expand into its deployed configuration where it may then fully expand into deployment. In yet additional variations, a heating or cooling element (e.g., heated or cooled liquid or gas, Peltier junction, etc.) may be deployed with a deployment instrument or separate from the expander to adjustably heat or cool the expander to allow for its re-configuration into its deployed configuration.
[0065] The urethral expanders may be configured in a number of different embodiments. With any of the different configurations, a single expander (e.g., having one or more ring-like structures or coils) may be deployed within the lumen or several expanders (e.g., 2 to 20 expanders or more) may be deployed adjacent to one another. In other variations, 2 to 4 expanders (e.g., each expander having one or more ring-like structures or coils) may be deployed while in other variations, 3 expanders may be deployed. When deployed, sufficient spacing (e.g., spacing may range anywhere from, e.g., 3 mm to 20 mm) may be provided between adjacent expanders along the prostatic urethra PU to allow for the invagination of the expanders by the tissue wall. The spacing between the expanders shall be optimized to permanently relieve the obstruction while minimizing the total amount of material placed in the urethra to avoid tissue irritation or encrustation. Alternatively, the expanders may be deployed to overlap with respect to adjacent expanders. These several expanders may be deployed in a sequential or connected manner within the prostatic urethra PU that facilitates an open passageway from the bladder BL to the membranous urethra MU.
[0066] One variation is shown in the top view of
[0067] Another variation is shown in the top and perspective views of
[0068] Optionally, the expander structure may also incorporate an anchoring mechanism to facilitate securement of the structure to the surrounding tissue and to prevent its migration when in use. One variation of the anchoring mechanism may be seen in the top and perspective view of
[0069] In yet another variation of an expander structure, the expander 70 may be configured into a collapsible structure forming a pattern, e.g., a zig-zag, coiled, sinusoidal, or other pattern, defining an opening 72 which may facilitate the collapse and expansion of the expander 70 along its circumference, as shown in the perspective view of
[0070] Another variation of the expander structure may be seen in the top views of
[0071] In yet another variation,
[0072] Other variations may be further seen in the perspective views of
[0073] Furthermore, although these ring-like structures are formed as a single expander assembly, the spacing between the ring-like structures may be similar to the deployed spacing between the individual expanders described herein. The distance between the structures may accordingly range anywhere from, e.g., 3 mm to 20 mm apart from one another to facilitate tissue epithelialization of the structure. Moreover, the distance between adjacent ring-like structures may be applied to any of the various embodiments described herein.
[0074] Moreover, the variation shown has three ring-like structures 110A, 110B, 110C for positioning along each of the three main lobes of the prostate PR so that the ring-like structures 110A, 110B, 110C may become invaginated within the tissues of their respective lobes. Although alternative variations may include a structure having fewer than three or more than three ring-like structures as well as structures which are non-circular in shape but which may include any number of other shapes, as described herein.
[0075]
[0076]
[0077]
[0078]
[0079]
[0080] The blunt and atraumatic tips on the ring-like structure may be optionally incorporated into any of the expander embodiments described herein, as practicable. For instance, the embodiments shown in any of the figures such as
[0081]
[0082] Each of the expander configurations shown utilizing three structures (e.g., for positioning against each of the three main lobes of the prostate PR) may be altered in other variations to include fewer than three structures or more than three structures. Moreover, the relative spacing between the structures may also be varied and the structures themselves may be angled with respect to one another as well. Additionally, any of the structures may optionally incorporate any of the surface modifications such as anchoring mechanisms or various coatings or coverings, as described herein, in any number of various combinations.
[0083] In deploying any of the various expander assemblies described herein, various instruments may be employed. One example is shown in the side view of
[0084] In other variations, as shown in the side view of
[0085] Once the expander assembly has been delivered from the instrument 210, the expander may reconfigure itself through its superelastic or shape memory properties into its deployed and expanded configuration into contact against the tissue walls. Alternatively, other actuation mechanisms, as described herein, may be used to reconfigure or facilitate reconfiguration of the expander.
[0086] The deployment instrument 210 may be advanced and positioned within the body lumen using an intraluminal visualization system, for example, an endoscope or cystoscope having an imager 216 which may be integrated with the deployment instrument 210 or separated. The visualization system may be utilized either before or during the deployment procedure. In other variations, an external imaging modality (e.g., ultrasound, computed tomography, magnetic resonance imaging, etc.) may be used in combination with the deployment instrument (and/or intraluminal visualization system). In other variations, a balloon or other positioning reference system may be placed, e.g., within the bladder BL or elsewhere to ensure proper anatomic positioning of the expanders.
[0087] The system may also optionally include apparatus and methods for adjustment and/or retrieval of the one or more expanders. One embodiment of this aspect of the system may include a grasper mechanism (e.g., standard grasper tools may be used). Other variations may also include heating or cooling elements to adjust the device to facilitate adjustment and/or removal.
[0088] The applications of the disclosed invention discussed above are not limited to certain treatments or regions of the body, but may include any number of other treatments and areas of the body. Modification of the above-described methods and devices for carrying out the invention, and variations of aspects of the invention that are obvious to those of skill in the arts are intended to be within the scope of this disclosure. Moreover, various combinations of aspects between examples are also contemplated and are considered to be within the scope of this disclosure as well.